From what I've heard, that MD has been involved in successfully bringing three technologies to market, one of which is a widely used stent for surgery, so I'll stick with his call on the N-Assay. I can't agree with statements regarding his knowledge of valuation, as there is no valid reason to suppose he does not have that ability.
News 
Market Data 
Discover 
AI
